SIE aderisce al protocollo di autenticazione
SIE è affiliata a
Aggiornamento Clinico Scientifico
Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate specific antigen (PSA): a meta- analysis
A cura di Francesco Romanelli & Andrea Sansone
Boyle P, Koechlin A, Bota M, d'Onofrio A, Zaridze DG, Perrin P, Fitzpatrick J, Burnett AL, Boniol M.
BJU Int. 2016 Jan 18. doi: 10.1111/bju.13417. [Epub ahead of print]
To review and quantify the association between endogenous and exogenous testosterone and prostate specific antigen (PSA) and prostate cancer. METHODS:Literature searches were performed following the PRISMA guidelines.
LEGGI TUTTO
Aggiornamento Clinico Scientifico Weight Loss and Health Status 3 Years after Bariatric Surgery in Adolescents
A cura di Flavia Prodam
Inge TH, Courcoulas AP, Jenkins TM, Michalsky MP, Helmrath MA, Brandt ML, Harmon CM, Zeller MH, Chen MK, Xanthakos SA, Horlick M, Buncher CR
Teen-LABS Consortium - N Engl JMed.2016;374:113-123.
BACKGROUND: Bariatric surgery is increasingly considered for the treatment of adolescents with severe obesity, but few prospective adolescent-specific studies examining the efficacy and safety of weight- loss surgery are available to support clinical decision making.
LEGGI TUTTO
Aggiornamento Clinico Scientifico Thiazide-associated hypercalcemia: incidence and association with primary hyperparathyroidism over two decades.
A cura di Massimo Procopio
Griebeler ML, Kearns AE, Ryu E, Thapa P, Hathcock MA, Melton LJ, Wermers RA.
J Clin Endocrinol Metab. 2016 doi: 10.1210/jc.2015- 39
Context:Thiazide diuretics,the antihypertensive agent prescribed most frequently worldwide,are commonly associated with hypercalcemia. However, the epidemiology and clinical features are poorly understood.
LEGGI TUTTO
Aggiornamento Clinico Scientifico Outcomes in Relapsed Graves' Disease Patients Following Radioiodine or Prolonged Low Dose of Methimazole Treatment
a cura di Tania Pilli
Villagelin D, Romaldini JH, Santos RB, Milkos AB, Ward LS.
Background: Low doses of antithyroid drugs (ATD) for extended periods may be an alternative for Graves' disease (GD) patients who relapse after a course of ATD
LEGGI TUTTO
Aggiornamento Clinico Scientifico Increased Hair Cortisol Concentrations and BMI in Patients With Pituitary-Adrenal Disease on Hydrocortisone Replacement
a cura di Andrea Lania
Sabine M. Staufenbiel, Cornelie D. Andela, Laura Manenschijn, Alberto M. Pereira, Elisabeth F. C. van Rossum, and Nienke R. Biermasz
J Clin Endocrinol Metab. 2015 Jun;100(6):2456-62
Intrinsic imperfections and lack of reliable biomarkers preclude optimal individual dosing of hydrocortisone replacement in adrenal insufficiency (AI). However, the clinical relevance of optimal dosing
LEGGI TUTTO
Aggiornamento Clinico Scientifico Sex Differences in the Cardiovascular Consequences of Diabetes Mellitus. A Scientific Statement From the American Heart Association
a cura di Daniele Gianfrilli
Regensteiner J.G., Golden S., Huebschmann A. G., Barrett-Connor E., Chang A. Y., Chyun D., Fox C. S., Kim C., Mehta N., Reckelhoff J. F., Reusch J. E.B., Rexrode K. M., Summer A. E., Welty F. K., Wenger N. K. and Anton B.
Circulation. 2015 Dec 22;132(25):2424-47
The prevalence of diabetes mellitus (DM) is increasing at a rapid rate. In the United State in 2012, 29.1 million Americans, or 9.3% of the population, had DM. Currently, ~1 in 13 people living in the United States has DM, and 90% to 95% of these individuals have type 2 DM (T2DM).
LEGGI TUTTO
Aggiornamento Clinico ScientificoPrevalence of autoimmune disease in patients with prolactinomas and non-functioning pituitary adenomas.
a cura di Annamaria De Bellis
Larouche V, Correa JA, Cassidy P, Beauregard C, Garfield N, Rivera J.
Pituitary. 2015 Dec 23.
Prolactin can affect autoimmune response and evidence suggests that hyperprolactinemia can primarily precipitate autoimmunity. We postulate that patients with prolactinomas are more prone to autoimmune disease (AID).
LEGGI TUTTO
Aggiornamento Clinico ScientificoEffect of testosterone treatment on cardiac biomarkers in a randomized controlled trial of men with type 2 diabetes
a cura di Giuseppe Bellastella
Emily J. Gianatti, Rudolf Hoermann, Que Lam, Philippe Dupuis, Jeffrey D. Zajac, and Mathis Grossmann
Clinical Endocrinology (2016) 84, 55–62
To assess the effect of testosterone treatment on cardiac biomarkers in men with type 2 diabetes (T2D). Design Randomized double-blind, parallel, placebo-controlled trial. Patients Men aged 35– 70 years with T2D and a total testosterone level
LEGGI TUTTO
Aggiornamento Clinico ScientificoMetformin as firstline treatment for type 2 diabetes: are we sure?
a curadi Marco Giorgio Baroni
Boussageon R, Gueyffier F, Cornu C.
BMJ. 2016 Jan 8;352:h6748.
Metformin is recommended as the first glucose lowering treatment for people with type 2 diabetes.1 The recommendation is based on the supposedly conclusive results of the UK Prospective Diabetes Study (UKPDS 34) published in 1998.
LEGGI TUTTO
Appuntamento Open AIFA
Roma, 14 ottobre 2015, ore 10:30 - Società Italiana di Endocrinologia (SIE)
Incontro avvenuto in presenza del Dr. L. Pani
LEGGI TUTTO
Stoccolma [...]
Roma [...]
Firenze [...]
